Selpercatinib versus multi-kinase inhibitors for advanced medullary thyroid cancer: A network meta-analysis of RET-targeted therapies
BackgroundSeveral RET-targeted agents, including highly selective RET inhibitors (SRIs) and multi-kinase inhibitors (MKIs), have been approved for the treatment of advanced medullary thyroid cancer (MTC). Despite these agents targeting the same pathway, direct comparative data is lacking. This study...
保存先:
| 主要な著者: | , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Frontiers Media S.A.
2026-06-01
|
| シリーズ: | Frontiers in Endocrinology |
| 主題: | |
| オンライン･アクセス: | https://www.frontiersin.org/articles/10.3389/fendo.2026.1851074/full |
| タグ: |
タグなし, このレコードへの初めてのタグを付けませんか!
|